FDA Approves Pioneering Microbiome Medicine VOWST, Offering Hope in the Fight Against C. difficile Infections
In a remarkable advancement for the biologics market, the US Food and Drug Administration (FDA) has given its approval to VOWST, a breakthrough orally administered fecal microbiota product. Developed by GenIbet Biopharmaceuticals, a subsidiary of Recipharm, VOWST will be used to prevent recurrent Clostridioides difficile infections (CDI) in adults who have previously undergone antibacterial treatment…